|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0275 AUD | +10.00% |
|
-.--% | -.--% |
| Feb. 26 | Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| 2023 | Exopharm to Cut CEO Role Amid Cost Reductions | MT |
Exopharm Limited reported earnings results for the full year ended June 30, 2023. For the full year, the company reported sales was AUD 0.618568 million compared to AUD 0.09973 million a year ago. Net loss was AUD 7.13 million compared to AUD 10.08 million a year ago.
Basic loss per share from continuing operations was AUD 0.0905 compared to AUD 0.1605 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 3.15M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
EXOPHARM LIMITED 
